Kit for the preparation of technetium tc-99m albumin aggregated - Biologic Drug Details

Summary for kit for the preparation of technetium tc-99m albumin aggregated

Tradenames:	4
High Confidence Patents:	0
Applicants:	3
BLAs:	4
Suppliers: see list	2

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for kit for the preparation of technetium tc-99m albumin aggregated Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for kit for the preparation of technetium tc-99m albumin aggregated Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for kit for the preparation of technetium tc-99m albumin aggregated Derived from Patent Text Search

No patents found based on company disclosures

Kit for the preparation of technetium tc-99m albumin aggregated Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Biologic Drugs: Focus on Technetium Tc-99m Albumin Aggregated

Introduction

The biologics market, which includes products like the kit for the preparation of Technetium Tc-99m Albumin Aggregated, is experiencing significant growth driven by various factors. This article delves into the market dynamics and financial trajectory of biologic drugs, with a specific focus on Technetium Tc-99m Albumin Aggregated.

Global Biologics Market Overview

The global biologics market is projected to reach USD 699.5 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.8% from 2024 to 2032. This growth is fueled by the increasing prevalence of chronic diseases, technological advancements, and the rising adoption of biosimilars[1].

Technetium Tc-99m Albumin Aggregated: An Overview

Technetium Tc-99m Albumin Aggregated is a radiopharmaceutical used primarily for assessing lung perfusion and evaluating the patency of peritoneovenous (LeVeen) shunts. It is prepared using albumin aggregated, which is denatured and aggregated through a heating process[3].

Market Drivers

Several factors are driving the growth of the biologics market, including:

Increasing Burden of Chronic Diseases

The rising prevalence of chronic and lifestyle-related diseases is a significant driver. These conditions often require targeted and advanced therapies, which biologics can provide[1].

Technological Advancements

Continuous technological advancements are facilitating the development of more targeted and effective biologic therapies. This includes improvements in drug delivery systems and manufacturing processes[1].

Growing Adoption of Biosimilars

Biosimilars, which are biologic products that are highly similar to an already approved biologic, are gaining traction due to their affordability and efficacy. This segment is expected to grow significantly, contributing to the overall market growth[4].

Improved Healthcare Infrastructure

Investments in healthcare infrastructure, particularly in regions like the Middle East and Africa, are enhancing the accessibility and quality of biologic treatments. Countries such as Saudi Arabia and South Africa are investing heavily in biotechnology and modernizing their medical facilities[1].

Financial Trajectory

Current Market Size

The biologics market, which includes products like Technetium Tc-99m Albumin Aggregated, was valued at USD 349.6 billion in 2023. This figure is expected to more than double by 2032, reaching USD 699.5 billion[1].

Growth Rate

The market is anticipated to grow at a CAGR of 7.8% from 2024 to 2032. This growth rate is driven by the increasing demand for biologic therapies and the expanding pipeline of biologic drugs[1].

Regional Growth

North America currently holds a substantial value share of the biologics market, but regions like China and India are expected to exhibit higher growth rates. China is predicted to grow at a CAGR of 8.8% and India at a CAGR of 8.5% from 2024 to 2034[4].

Technetium Tc-99m Albumin Aggregated: Specific Market Dynamics

Clinical Use

Technetium Tc-99m Albumin Aggregated is used for specific diagnostic purposes, such as assessing lung perfusion and evaluating the patency of peritoneovenous shunts. Its use is critical in certain medical procedures, ensuring a steady demand within the healthcare sector[3].

Production and Distribution

The production of Technetium Tc-99m Albumin Aggregated involves the aggregation of albumin through a heating process. The product is supplied in kits that include the necessary ingredients for preparing the radiopharmaceutical. Distribution channels, particularly pharmacies, play a crucial role in making these kits accessible to healthcare providers[2].

Regulatory Approvals

Regulatory approvals are a significant factor in the market dynamics of biologic drugs. The escalating approvals of biologics by regulatory agencies are driving market growth. For Technetium Tc-99m Albumin Aggregated, compliance with regulatory standards is essential for its continued use and market presence[1].

Competitive Landscape

The biologics market is highly competitive, with several key players involved in the development and distribution of biologic drugs. Manufacturers with long-standing experience in biologics production possess valuable expertise in process development, optimization, and quality assurance, which is crucial for maintaining market share[4].

Future Outlook

Emerging Trends

Emerging trends in the biologics market include the increasing use of monoclonal antibodies and the development of more targeted therapeutic approaches. These trends are expected to further drive the growth of the market[4].

Challenges and Opportunities

Despite the growth potential, the biologics market faces challenges such as high development costs, complex manufacturing processes, and stringent regulatory requirements. However, these challenges also present opportunities for innovation and improvement in biologic drug development and production.

Key Takeaways

• The global biologics market is projected to reach USD 699.5 billion by 2032, driven by the increasing prevalence of chronic diseases and technological advancements.
• Technetium Tc-99m Albumin Aggregated is a critical radiopharmaceutical used for diagnostic purposes, with a steady demand in the healthcare sector.
• The market growth is supported by improving healthcare infrastructure, growing adoption of biosimilars, and escalating regulatory approvals.
• Regional growth, particularly in China and India, is expected to be significant, driven by increasing healthcare investments and demand for advanced medical treatments.

FAQs

Q: What is the projected growth rate of the biologics market from 2024 to 2032?

A: The biologics market is expected to grow at a CAGR of 7.8% from 2024 to 2032[1].

Q: What are the primary uses of Technetium Tc-99m Albumin Aggregated?

A: Technetium Tc-99m Albumin Aggregated is used for assessing lung perfusion and evaluating the patency of peritoneovenous (LeVeen) shunts[3].

Q: Which regions are expected to exhibit high growth rates in the biologics market?

A: China and India are predicted to exhibit high growth rates, with China growing at a CAGR of 8.8% and India at a CAGR of 8.5% from 2024 to 2034[4].

Q: What factors are driving the growth of the biologics market?

A: The growth is driven by the increasing prevalence of chronic diseases, technological advancements, growing adoption of biosimilars, and improving healthcare infrastructure[1].

Q: What is the role of regulatory approvals in the biologics market?

A: Regulatory approvals are crucial for the market growth of biologics, as they ensure the safety and efficacy of these drugs and facilitate their entry into the market[1].

Sources

1. Biologics Market Size to Reach USD 699.5 Billion by 2032, Impelled by Emergence of Advanced Drug Delivery Systems. Biospace.
2. Kit for the Preparation of Technetium Tc 99m Albumin Aggregated Injection. Pharmacyce.unm.edu.
3. Albumin Aggregated: Uses, Interactions, Mechanism of Action. DrugBank.
4. Biosimilar and Biologics Market Is Expected to Reach USD 1,060.7 Billion by 2034. GlobeNewswire.
5. Macroaggregated Albumin MAA: Topics by Science.gov. Science.gov.